New drug cocktail offers hope for debilitating ear disorder
NCT ID NCT05582837
First seen Apr 16, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests whether a combination of two medications, nortriptyline and topiramate, can improve symptoms of Meniere's disease, a chronic inner ear disorder that causes vertigo, hearing loss, and tinnitus. The trial will involve 40 adults with active Meniere's disease. Participants will receive either the drug combo or a placebo, and researchers will measure changes in quality of life and symptom severity over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MÉNIÈRE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Irvine Medical Center ENT Clinic (Pavilion 2)
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.